证券代码：000597 证券简称：东北制药 公告编号：2025-060 根据《公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等法律法规及《公司章程》的有关规定，其辞职报告自送达公 司董事会之日起生效。周雅娜女士辞去公司财务总监职务不会影响公司相关工作 的正常进行。公司董事会将根据相关规定尽快聘任财务总监。在聘任财务总监之 前，由公司董事、总经理蔡永刚先生代为行使财务总监职责。 截至本公告披露日，周雅娜女士持有公司股份 120,000 股。辞去公司财务总 监职务后，其所持股份将继续按照《上市公司董事、监事和高级管理人员所持本 公司股份及其变动管理规则》《深圳证券交易所股票上市规则》《深圳证券交易 所上市公司自律监管指引第 18 号——股东及董事、监事、高级管理人员减持股 份》等相关规定进行管理。 周雅娜女士在担任公司财务总监期间，勤勉、忠实地履行了相关职责和义务， 公司及董事会对周雅娜女士表示衷心感谢！ 特此公告。 东北制药集团股份有限公司董事会 东北制药集团股份有限公司关于公司财务总监辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导 ...

Core Viewpoint - The resignation of the Chief Financial Officer (CFO) of Northeast Pharmaceutical Group Co., Ltd. due to personal health reasons will not affect the company's normal operations [1] Group 1 - The CFO, Zhou Yana, submitted a written resignation report to the board of directors [1] - The resignation is effective immediately upon delivery to the board [1] - The board will promptly appoint a new CFO, with current director and general manager Cai Yonggang acting in the interim [1] Group 2 - As of the announcement date, Zhou Yana holds 120,000 shares of the company [1] - The management of her shares will follow relevant regulations [1]

Group 1 - The core viewpoint of the article is that Northeast Pharmaceutical (000597.SZ) has seen an increase in institutional investor holdings, reaching a total of 8.13 billion shares, which accounts for 56.98% of the company's total equity as of August 27, 2025 [1] - The number of institutional investors holding shares in Northeast Pharmaceutical has increased to five, with a rise in the institutional holding ratio by 1.37 percentage points compared to the previous quarter [1] - Among public funds, there was one fund, Southern CSI 1000 ETF, that increased its holdings, while another fund, Galaxy Kang Le Stock A, saw a slight decrease in its holdings compared to the previous quarter [1] Group 2 - Foreign investment sentiment shows that one foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.21% compared to the previous period [1]

Core Viewpoint - Northeast Pharmaceutical is actively enhancing its talent acquisition and innovation capabilities through a series of strategic initiatives, including the recruitment of high-level graduates and the establishment of a comprehensive R&D ecosystem to drive long-term growth and transformation [1][2][3]. Group 1: Talent Acquisition and Training - The company has initiated a month-long training program for over 100 newly recruited master's and doctoral graduates from prestigious universities, marking a significant step in its talent acquisition strategy [1][2]. - Northeast Pharmaceutical has conducted extensive recruitment efforts, including 35 recruitment events across 28 universities, selecting top candidates from over 1,600 applications [2]. - The company provides upgraded living accommodations for new hires, ensuring a smooth transition into their roles [2]. Group 2: Innovation and R&D Focus - The company is committed to enhancing its R&D capabilities by focusing on drug innovation, chemical drug transformation, cell therapy breakthroughs, and modernization of traditional Chinese medicine [2][6]. - Northeast Pharmaceutical has established a robust incentive mechanism to support high-quality research projects and reward significant breakthroughs, fostering a culture of innovation [2][3]. - The company aims to leverage its recent recruitment of high-level talent to strengthen its R&D team and expand its competitive edge in the biopharmaceutical sector [3][7]. Group 3: Strategic Transformation and Market Positioning - Northeast Pharmaceutical is undergoing a strategic transformation to adapt to changes in the pharmaceutical industry, with a focus on developing a complete industrial chain and enhancing its product pipeline [6]. - The company has made significant investments in acquiring technology and product lines, particularly through the acquisition of Beijing Dingcheng Peptide Source, positioning itself in the first tier of the cell therapy market [6][7]. - The company is actively developing over ten cell therapy products targeting various cancers, aiming to establish a competitive advantage in the biopharmaceutical market [6][7].

Core Viewpoint - Northeast Pharmaceutical is actively enhancing its talent acquisition and research capabilities to drive innovation and strategic transformation in response to industry changes and market demands [1][3][4]. Group 1: Talent Acquisition and Training - The company has recruited over 100 master's and doctoral graduates from prestigious universities, initiating a one-month training program to prepare them for various roles within the organization [1][2]. - Northeast Pharmaceutical's recruitment efforts included 35 events across 28 universities, selecting from over 1,600 resumes to find top talent [2]. - The company has established a comprehensive incentive mechanism to support high-quality research projects and provide substantial rewards for significant breakthroughs, fostering a talent growth ecosystem [2][3]. Group 2: Research and Development Focus - The company is focusing on drug research and innovation, particularly in chemical drug transformation, cell therapy technology breakthroughs, and modernization of traditional Chinese medicine [1][3]. - Northeast Pharmaceutical aims to strengthen its competitive edge in the generic drug sector while also making strides in the biopharmaceutical field, leveraging the recent recruitment of high-end talent [3][4]. - The acquisition of Beijing Dingcheng Peptide Source has enabled the company to enter the cell therapy market, developing over ten cell therapy products targeting various cancers [4][5]. Group 3: Employee Benefits and Retention Strategies - Northeast Pharmaceutical offers competitive salaries and unique benefits, including medical expense assistance, mobile phone allowances, and family-oriented programs, to enhance employee satisfaction and retention [3]. - The company emphasizes a people-oriented approach, aiming to create a supportive environment that fosters loyalty and commitment among employees [3].

Core Insights - The company's total revenue for the current period is approximately 3.85 billion, a decrease from 4.17 billion in the same period last year, indicating a decline in overall revenue [1] Revenue Breakdown by Industry - Pharmaceutical manufacturing generated approximately 2.00 billion, accounting for 52.00% of total revenue, compared to 2.20 billion and 52.67% in the previous year [1] - Pharmaceutical commerce contributed around 1.78 billion, representing 46.18% of total revenue, up from 1.90 billion and 45.67% year-on-year [1] - Other segments accounted for 70.23 million, or 1.82% of total revenue, slightly increasing from 69.08 million and 1.66% [1] Revenue Breakdown by Product - Raw material sales were approximately 663.46 million, making up 17.22% of total revenue, compared to 667.44 million and 16.01% last year [1] - Formulation sales totaled around 1.32 billion, representing 34.17% of total revenue, down from 1.52 billion and 36.36% [1] - Other product sales accounted for about 1.87 billion, or 48.61% of total revenue, increasing from 1.99 billion and 47.63% [1] Revenue Breakdown by Region - Export revenue was approximately 608.20 million, representing 15.79% of total revenue, compared to 415.56 million and 9.97% in the previous year [1] - Domestic sales accounted for around 3.24 billion, or 84.21% of total revenue, down from 3.75 billion and 90.03% [1] Cell Therapy Product Development - The company has established a comprehensive technology platform and product transformation system for cell therapy products, including TCR-T, CAR-T, and SNK [1] - The company has developed over ten cell therapy products targeting KRAS mutations, EGFRvIII, Claudin18.2, among others, for treating advanced pancreatic cancer, colorectal cancer, gastric cancer, liver cancer, and glioblastoma [1]

Group 1 - The core viewpoint of the article highlights the growth in the number of enterprises in the chemical raw materials and chemical products manufacturing industry, which increased by 1,021 to a total of 26,860 enterprises in the first half of 2025, representing a year-on-year growth of 3.95% [1] - The proportion of chemical raw materials and chemical products manufacturing enterprises in the total industrial enterprises is 5.16% [1] - The report referenced is the "2025-2031 China Basic Chemical Raw Materials Industry Market Supply and Demand Situation and Investment Prospects Analysis Report" published by Zhiyan Consulting [1] Group 2 - The data indicates that the threshold for scale industrial enterprises has been raised from an annual main business income of 5 million yuan to 20 million yuan since 2011 [1] - Zhiyan Consulting is recognized as a leading industry consulting agency in China, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1] - The consulting firm emphasizes its commitment to delivering quality services and market insights to empower investment decisions [1]

Core Insights - Northeast Pharmaceutical has achieved an average self-maintenance rate of over 97% in the past three years, saving over 10 million yuan in costs, demonstrating effective cost reduction and efficiency improvement through a self-maintenance model empowered by refined management [1][4]. Group 1: Innovative Maintenance Model - The company has shifted from a traditional reliance on external maintenance to a self-maintenance model, focusing on refined management to enhance cost control, efficiency, and technical independence [1][4]. - A technical task force was established to promote innovation, with responsibilities divided among team members, leading to a transformation from a rough maintenance approach to a lean one [2][3]. Group 2: Efficiency and Quality Improvement - The implementation of a "three ones" work method has ensured high-quality completion of maintenance tasks, with specific projects led by party members and technical challenges tackled by dedicated teams [3]. - The energy assurance center completed the self-cleaning of a 6000 cubic meter circulating water pool in 7 days, significantly improving cleaning quality and efficiency [3]. Group 3: Long-term Mechanism for Cost Reduction - Northeast Pharmaceutical has established a long-term mechanism to sustain the value of self-maintenance, including regular technical challenges and talent development [4]. - The company conducts nearly 2000 maintenance projects annually, with a self-conducted rate exceeding 97%, further embedding the principles of refined management into its operational culture [4].

格隆汇8月26日丨东北制药(000597.SZ)公布2025年半年度报告，上半年公司实现营业收入38.53亿元，同 比下降7.58%；归属于上市公司股东的净利润1.29亿元，同比下降17.62%；归属于上市公司股东的扣除 非经常性损益的净利润8935.74万元，同比下降14.54%；基本每股收益0.090元。 ...

1、合并资产负债表 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 3,829,248,601.20 | 4,468,332,416.81 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 424,728,306.28 | 534,622,306.52 | | 应收账款 | 2,323,800,948.99 | 1,959,029,870.69 | | 应收款项融资 | | | | 预付款项 | 51,865,442.44 | 140,839,635.54 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 229,492,889.13 | 192,507,181.41 | | 其中：应收利息 | | | | 应收股利 | | | | 买入返售金融资产 | | | | 存货 | 1,272,769,661.86 | 1,323,826,723.69 | | 其中：数据资源 | | ...